OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) reported consolidated revenue of \u20b92.9 billion for the quarter ended December 31, 2025, a decline of 26% year-on-year, according to its Q3 FY26 earnings release. EBITDA stood at \u20b9173 million, down 88% from the corresponding quarter last year, while adjusted profit after tax was a loss of \u20b9472 million. The company attributed the performance to delays in customer approvals for semaglutide in Canada, which led to revenue deferrals during the quarter.<\/p>\n\n\n\n
Business Overview<\/strong><\/h2>\n\n\n\n
OneSource Specialty Pharma operates as a contract development and manufacturing organisation (CDMO) focused on complex pharmaceutical products, including biologics, drug-device combinations, sterile injectables, and oral technologies such as soft gelatin capsules. The company operates five manufacturing facilities and serves global pharmaceutical customers across multiple therapeutic and technology platforms.<\/p>\n\n\n\n
Financial Performance<\/strong><\/h2>\n\n\n\n
Revenue for Q3 FY26 was \u20b92,903 million, compared with \u20b93,758 million in Q2 FY26 and \u20b93,926 million in Q3 FY25. EBITDA for the quarter was \u20b9173 million, compared with \u20b91,065 million in the preceding quarter and \u20b91,419 million in the same quarter last year. EBITDA margin was 6%, compared with 28% in Q2 FY26 and 36% in Q3 FY25.<\/p>\n\n\n\n
Adjusted PAT for Q3 FY26 was a loss of \u20b9472 million, compared with \u20b9449 million in Q2 FY26 and \u20b9672 million in Q3 FY25. Adjusted EPS stood at \u20b9(4.1).<\/p>\n\n\n\n
The company stated that lower revenue combined with a largely fixed cost base affected profitability during the quarter.<\/p>\n\n\n\n
Operating Metrics<\/strong><\/h2>\n\n\n\n
OneSource reported revenue of $33.1 million in Q3 FY26, compared with $42.9 million in Q2 FY26 and $44.8 million in Q3 FY25. The company reported EBITDA of $2.0 million and an EBITDA margin of 6%.<\/p>\n\n\n\n
The company highlighted continued growth in its biologics pipeline, onboarding of a global biosimilar customer, and expansion of its project funnel with more than 10 biologics projects at various stages.<\/p>\n\n\n\n
During the quarter, OneSource signed multiple new master service agreements and licensing deals, with a significant portion of new business coming from existing customers.<\/p>\n\n\n\n
Key Developments<\/strong><\/h2>\n\n\n\n
The board approved unaudited standalone and consolidated financial results for the quarter and declared a third interim dividend of \u20b94 per equity share, with January 31, 2026 set as the record date.<\/p>\n\n\n\n
The company reiterated its FY28 outlook, targeting organic revenue of $400 million and $500 million including a proposed acquisition, with an EBITDA margin outlook of around 40%, subject to approvals.<\/p>\n\n\n\n
Risks and Constraints<\/strong><\/h2>\n\n\n\n
The company noted that delays in regulatory approvals and customer transitions affected revenue recognition during the quarter, highlighting the dependence of performance on regulatory timelines and customer approvals.<\/p>\n\n\n\n
Outlook \/ Guidance<\/strong><\/h2>\n\n\n\n
OneSource reaffirmed its medium-term growth outlook and stated that demand in its core business remains intact, supported by an expanding order book and biologics pipeline.<\/p>\n\n\n\n<\/figure>\n\n\n\n<\/figure>\n","protected":false},"excerpt":{"rendered":"
OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) reported consolidated revenue of \u20b92.9 billion for the quarter ended December 31, 2025, a decline of 26% year-on-year, according to its Q3 FY26 earnings release. EBITDA stood at \u20b9173 million, down 88% from the corresponding quarter last year, while adjusted profit after tax was a loss […]<\/p>\n","protected":false},"author":2390,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,1941,5747,5],"tags":[14743,14741,14746,14744,14580,14496,14747,14742,14745,14738,14737,14736,14739,14559,14740],"class_list":["post-177629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-stock-analysis","category-healthcare-stocks","category-latest","tag-biologics-manufacturing","tag-bse-544292","tag-cdmo-sector-india","tag-contract-manufacturing-pharma","tag-corporate-earnings-india","tag-indian-stock-market","tag-nse-onesource","tag-onesource-earnings","tag-onesource-q3-fy26","tag-onesource-results","tag-onesource-specialty-pharma","tag-onesource-specialty-pharma-ltd","tag-onesource-stock","tag-quarterly-results-india","tag-specialty-pharma-india"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":177650,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-operational-scale-expands-amid-near-term-earnings-volatility\/","url_meta":{"origin":177629,"position":0},"title":"OneSource Specialty Pharma Ltd operational scale expands amid near-term earnings volatility","author":"Staff Correspondent","date":"January 24, 2026","format":false,"excerpt":"OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) has emerged as a multi-modality contract development and manufacturing organisation (CDMO) following the integration of biologics, drug-device combinations, sterile injectables, and oral technologies businesses. While near-term financial performance in Q3 FY26 was affected by regulatory approval delays and revenue deferrals, disclosures\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":175850,"url":"https:\/\/alphastreet.com\/india\/strides-pharma-science-limited-star-q2-2025-earnings-call-transcript\/","url_meta":{"origin":177629,"position":1},"title":"Strides Pharma Science Limited (STAR) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Strides Pharma Science Limited (NSE: STAR) Q2 2025 Earnings Call dated Oct. 24, 2024 Corporate Participants: Abhishek Singhal \u2014 Investor Relations Arun Kumar \u2014 Executive Chairperson Analysts: Rupesh Tatiya \u2014 Analyst Naman Bhansali \u2014 Analyst Nitin Agarwal \u2014 Analyst Abdulkader Puranwala \u2014 Analyst Aman Vij \u2014 Analyst Ritesh Oswal \u2014\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174424,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-onesource-q3-2025-earnings-call-transcript\/","url_meta":{"origin":177629,"position":2},"title":"Onesource Specialty Pharma Ltd (ONESOURCE) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Onesource Specialty Pharma Ltd (NSE: ONESOURCE) Q3 2025 Earnings Call dated Jan. 29, 2025 Corporate Participants: Unidentified Speaker Arun Kumar \u2014 Founder and Non-Executive Director Neeraj Sharma \u2014 Chief Executive Officer and Managing Director Anurag Bhagania \u2014 Chief Financial Officer Analysts: Nitin Agarwal \u2014 Anallyst Amey Chalke \u2014 Analyst Kunal\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177620,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-onesource-q3-2026-earnings-call-transcript\/","url_meta":{"origin":177629,"position":3},"title":"Onesource Specialty Pharma Ltd (ONESOURCE) Q3 2026 Earnings Call Transcript","author":"News desk","date":"January 26, 2026","format":false,"excerpt":"Onesource Specialty Pharma Ltd (NSE: ONESOURCE) Q3 2026 Earnings Call dated Jan. 24, 2026 Corporate Participants: Arun Kumar \u2014 Founder and Non-Executive Director Neeraj Sharma \u2014 Chief Executive Officer and Managing Director Anurag Bhagania \u2014 Chief Financial Officer Abhishek Singhal \u2014 Company Secretary Analysts: Unidentified Participant Abdulkader Puranwala \u2014 Analyst\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":175849,"url":"https:\/\/alphastreet.com\/india\/strides-pharma-science-limited-star-q3-2025-earnings-call-transcript\/","url_meta":{"origin":177629,"position":4},"title":"Strides Pharma Science Limited (STAR) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Strides Pharma Science Limited (NSE: STAR) Q3 2025 Earnings Call dated Jan. 30, 2025 Corporate Participants: Arun Kumar \u2014 Executive Chairperson Badree Komandur \u2014 Managing Director & Group Chief Executive Officer Vikesh Kumar \u2014 Group Chief Financial Officer & Chief Investor Relations Officer Analysts: Abhishek Singhal \u2014 Analyst Analyst Nitin\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174423,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-onesource-q4-2025-earnings-call-transcript\/","url_meta":{"origin":177629,"position":5},"title":"Onesource Specialty Pharma Ltd (ONESOURCE) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Onesource Specialty Pharma Ltd (NSE: ONESOURCE) Q4 2025 Earnings Call dated May. 06, 2025 Corporate Participants: Unidentified Speaker Arun Kumar \u2014 Founder and Non-Executive Director Neeraj Sharma \u2014 Chief Executive Officer and Managing Director Anurag Bhagania \u2014 Chief Financial Officer Analysts: Unidentified Participant Aman \u2014 Analyst Madhav Marda \u2014 Analyst\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2390"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177629"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177629\/revisions"}],"predecessor-version":[{"id":177635,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177629\/revisions\/177635"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-57.png\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-58.png\")
<\/figure>\n","protected":false},"excerpt":{"rendered":"